Clinical Trial Update: Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC [Phase 2]

View source ↗

Summary

Phase 2 perioperative trial evaluating iparomlimab and tuvonralimab in resectable non-small cell lung cancer, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tuvonralimab (tuvonralimab)
• iparomlimab

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Non-small Cell Lung Cancer (NSCLC), II-IIIB | Phase 2 | Status: RECRUITING